Editors’ Picks, April 2024: Targeting Metabolism, KRAS, and More
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
Highlights of December 2023 AACR journals include clinical trial results, strategies to improve therapy, and a new cervical cancer...
Charles Swanton, MD, PhD, FAACR, spoke on the role chromosomal instability plays in breast cancer evolution.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
“What will you do Monday morning?” was the question posed by the final session on the final full day...
In 1994, at the age of 40, Ginny Mason, RN, began noticing some concerning differences in the size and...
In 2022, AACR launched a unique initiative called AACR Maximizing Opportunity for New Advancements in Research in Cancer (MONARCA)...
Studies featured at this year’s San Antonio Breast Cancer Symposium (SABCS) suggest that—in some situations—adjuvant radiotherapy may not be...
A breast cancer diagnosis can pose innumerable challenges, and with the average age at diagnosis dropping, the impact of...
Each December, an impressive cohort of breast cancer researchers gathers for the San Antonio Breast Cancer Symposium (SABCS), one...
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...